Last updated on May 2019

Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: head and neck cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Age >/= 18
  2. Histologically documented Squamous Cell Carcinoma of the oropharynx (American Joint Committee on Cancer (AJCC) v7** Stage III-IV A,B)
  3. Tumor tissue (primary or cervical metastasis) available for human papilloma virus (HPV) and/or p16 (in situ hybridization (ISH), immunohistochemistry (IHC) or genotyping testing) If you do not have enough leftover tumor tissue available, you will have a tumor biopsy for tumor marker testing.
  4. Eastern Cooperative Oncology Group (ECOG) performance status= 0, 1, or 2
  5. Negative pregnancy test for women of child bearing potential
  6. Concurrent Chemotherapy
  7. Bilateral Neck Radiation

Exclusion Criteria:

  1. Previous radiation treatment for head and neck mucosal primary cancers within the past 5 years (i.e. oropharynx, nasopharynx, hypopharynx, larynx, and oral cavity)
  2. Pregnant or breast-feeding females
  3. Clinically significant uncontrolled major cardiac, respiratory, renal, hepatic, gastrointestinal or hematologic disease but not limited to: a) Symptomatic congestive heart failure, unstable angina, or cardiac dysrrhythmia not controlled by pacer device. b) Myocardial infarction within 3 months of registration.
  4. Distant Metastases (Stage IV C, any T, any N and M1)
  5. Previous surgical resection or neck dissection for oropharyngeal cancer, administered with therapeutic intent.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.